Humacyte (NASDAQ:HUMA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a sell rating to a hold rating in a research note released on Thursday morning.

Several other research firms have also weighed in on HUMA. HC Wainwright assumed coverage on Humacyte in a research note on Wednesday, May 14th. They issued a “buy” rating and a $4.00 price objective on the stock. Benchmark lowered their price objective on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, May 13th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of “Moderate Buy” and an average price target of $11.71.

Humacyte Stock Up 5.4%

Shares of HUMA opened at $2.53 on Thursday. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.97. The firm has a market capitalization of $392.45 million, a price-to-earnings ratio of -1.89 and a beta of 1.64. The stock’s 50-day moving average price is $1.77 and its 200 day moving average price is $3.38.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. Equities research analysts expect that Humacyte will post -1.27 EPS for the current year.

Insider Buying and Selling

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CFO Dale A. Sander acquired 20,000 shares of Humacyte stock in a transaction on Thursday, April 10th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares in the company, valued at approximately $62,118. This represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 83,993 shares of company stock worth $118,224 in the last three months. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HUMA. Columbia Advisory Partners LLC acquired a new position in Humacyte during the 1st quarter worth $27,000. Hamilton Lane Advisors LLC acquired a new position in Humacyte during the 1st quarter worth $37,000. Letko Brosseau & Associates Inc. acquired a new position in Humacyte during the 1st quarter worth $42,000. Vontobel Holding Ltd. acquired a new position in shares of Humacyte in the 4th quarter valued at $50,000. Finally, Petros Family Wealth LLC acquired a new position in shares of Humacyte in the 4th quarter valued at $50,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.